Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16674694 | 0.93 | PLA2G7 (0.40) | PLA2G7CHRM2MEN1CYP1A2CYP2C19 | |
| SCHEMBL16674699 | 0.89 | MEN1 (0.47) | PLA2G7MEN1KMT2A | |
| SCHEMBL16674707 | 0.87 | PLA2G7 (0.36) | PLA2G7CHRM2MEN1CYP1A2CYP2C19 | |
| SCHEMBL16674695 | 0.81 | PLA2G7 (0.46) | PLA2G7MEN1KMT2A | |
| SCHEMBL7968322 | 0.79 | PLA2G7 (0.47) | PLA2G7 | |
| SCHEMBL6946605 | 0.77 | PLA2G7 (0.46) | PLA2G7 | |
| SCHEMBL11272468 | 0.77 | MGLL (0.47) | PLA2G7 | |
| SCHEMBL16674703 | 0.76 | HSP90AB1 (0.39) | PLA2G7 | |
| SCHEMBL1593903 | 0.76 | PLA2G7 (0.45) | PLA2G7 | |
| SCHEMBL16674696 | 0.75 | HSP90AB1 (0.33) | PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086740-A1 | BIOCIDAL COATINGS AND METHODS FOR MAKING SAME | EXIGENCE TECH INC (CA) | 2018-03-29 | — | — | US | disclosed |
| US-20170204085-A1 | BIOCIDAL COATINGS AND METHODS FOR MAKING SAME | EXIGENCE TECHNOLOGIES INC. (CA) | 2017-07-20 | — | — | US | disclosed |
| US-20150118179-A1 | BIOCIDAL COMPOUNDS AND METHODS FOR USING SAME | UNIVERSITY OF MANITOBA (CA) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204085-A1 | BIOCIDAL COATINGS AND METHODS FOR MAKING SAME | MPO, HNMT, TYR | PLA2G7 2186/4885CHRM2 2192/4885MEN1 1825/4885 |
| US-20150118179-A1 | BIOCIDAL COMPOUNDS AND METHODS FOR USING SAME | NQO2, DLAT, TYR | PLA2G7 3664/4885CHRM2 597/4885MEN1 3108/4885 |
| US-20180086740-A1 | BIOCIDAL COATINGS AND METHODS FOR MAKING SAME | BCHE, NHERF1, HCN3 | PLA2G7 2335/4885CHRM2 1293/4885MEN1 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.